The FDA cleared Bristol Myers Squibb's Zenbexus (iberdomide), the first drug in the new CELMoD class, for patients with relapsed or refractory multiple myeloma

Replimune's RP1, a genetically engineered oncolytic virus, received FDA approval for advanced melanoma that has not responded to prior therapies, expanding immu

Regeneron's investigational gene therapy for a form of genetic hearing loss received accelerated FDA approval, with a drug pricing deal with the White House exp

The FDA approved Moderna's mRNA-based flu vaccine, which the company says is more effective than current seasonal flu shots, expanding the mRNA platform beyond

Allogene Therapeutics received FDA accelerated approval for its CRISPR (TALEN)-edited allogeneic CAR T-cell therapy for lymphoma, a milestone for off-the-shelf

Researchers at UMass Chan Medical School showed that an mRNA-based immunotherapy eliminated pancreatic tumors in half of treated mice, a promising step for a no

Skye Biosciences and Redx Pharma agreed to merge in a reverse transaction valued at $125 million, pooling resources to develop fibrosis-focused therapies.

A new research award will fund a combination of KRAS-targeted therapy and immunotherapy for pancreatic cancer, aiming to attack one of the most challenging canc

Epicrispr raised $90 million to push its epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD) into pivotal trials, potentially the first medicin

The FDA approved the start of a Phase 3 trial for PhenoNet's inhaled PHENOGENE-1A gene therapy targeting early Alzheimer's disease.

The FDA granted a Type C meeting to discuss a therapy for pulmonary metastatic osteosarcoma, advancing potential treatment for this rare bone cancer.

Capricor Therapeutics shares rose after its CEO said the FDA is willing to review an updated submission for its Duchenne muscular dystrophy cell therapy followi

An LSD-based psychedelic therapy succeeded in two Phase 3 trials, but the developer now must navigate FDA approval and the challenges of commercializing a psych

Seattle-based InduPro raised $77 million and initiated its first-in-human clinical trial for a novel cancer therapy targeting protein interactions.

Boulevard launched with $65 million in financing to develop a new platform for autoimmune disease therapies, targeting conditions like lupus and rheumatoid arth

Perceptive Advisors is betting that the FDA rejected soticlestat's clinical trial design, not the drug itself, and plans to pursue a new development path for th

Khartis, founded by a Pfizer veteran, launched with $95 million to develop an oral treatment for thyroid eye disease, a condition currently treated with infusio

The FDA cleared a Phase 3 trial of denifanstat, a novel oral therapy for moderate to severe acne, advancing a potential non-antibiotic treatment option.